Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a mixed outlook. Positive revenue growth of 25% and a slight improvement in net loss are offset by increased R&D and G&A expenses. Regulatory hurdles, market conditions, and supply chain risks present uncertainties. The absence of shareholder return discussions and unclear management responses in the Q&A add to the neutral sentiment. The strategic initiatives are promising but hinge on future regulatory approvals and market conditions. Overall, the stock is likely to remain stable in the short term.
Key Financial Performance
Revenue Scholar Rock reported revenue of $15.2 million for Q1 2026, representing a 25% increase year-over-year. This growth was primarily driven by increased collaboration revenue from partnerships.
Research and Development (R&D) Expenses R&D expenses were $22.8 million, up 10% compared to the same period last year. The increase was attributed to higher costs associated with advancing clinical trials and expanding the R&D team.
General and Administrative (G&A) Expenses G&A expenses totaled $8.5 million, reflecting a 5% increase year-over-year. This rise was due to higher personnel costs and investments in infrastructure to support growth.
Net Loss The company reported a net loss of $16.1 million, which is a slight improvement from the $17.3 million net loss in Q1 2025. The improvement was due to higher revenue partially offsetting increased expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: Potential delays in regulatory approvals for new therapies could impact the company's ability to bring products to market on time.
Market Conditions: Unfavorable market conditions could affect the company's financial performance and ability to compete effectively.
Supply Chain Disruptions: Disruptions in the supply chain could lead to delays in product availability and increased costs.
Strategic Execution Risks: Challenges in executing strategic plans could hinder the company's growth and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Introductory Remarks: David Hallal, Chairman and CEO, will provide introductory remarks and a business update.
R&D Progress: Akshay Vaishnaw, President of R&D, will review R&D progress.
Commercial Readiness: Keith Woods, COO, will provide an update on commercial readiness activities.
Financial Update: Vikas Sinha, CFO, will provide a financial update.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amy Li
Bank Research
BofA Securities
CFO Treasurer
Canaccord Genuity
Citigroup Inc
Co Research
Corp Research
Cory Kasimov
Director Chief
Division Cory
Division Gary
Division Geoffrey
Division Lili
Division Marc
Division Wesley
Division Yee
EDT Hallal
Equities Research
Eric Schmidt
Evercore ISI
Exchange Research
Gary Nachman
Genuity Corp
Geoffrey Meacham
Holding EDT
ISI Institutional
Inc Exchange
LLC Research
Research Division
SRRK Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reflects a mixed outlook. Positive revenue growth of 25% and a slight improvement in net loss are offset by increased R&D and G&A expenses. Regulatory hurdles, market conditions, and supply chain risks present uncertainties. The absence of shareholder return discussions and unclear management responses in the Q&A add to the neutral sentiment. The strategic initiatives are promising but hinge on future regulatory approvals and market conditions. Overall, the stock is likely to remain stable in the short term.
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
SRRK Slides
SRRK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
